Celgene Corp. (CELG) shares soar on Supergen Inc's (SUPG) FDA stumble

Celgene Corp. (CELG) shares scored a high volume breakout yesterday trading up on over four times its 21-day average volume as its competitor Supergen Inc. (SUPG) had its Dacogen drug nixed at the FDA.  This negative FDA ruling allows Celgene to retain its 71 % market shares in the MDS market with its Revlimid and Vidaza drugs.  The point and figure target for CELG is $ 90.00.

View image


Comments
Leave a comment
Name
Email Address
URL
Remember personal info?
Comments
Blog Home
RSS Feed
Categories
Barron's
Breakouts/Breakdowns
ChartWatch
Company in the News
Earnings
Equity Timing Signals (Buy/Sell)
Index Study
Market Data
Media
New Highs
Sector Group Rankings
Short Squeeze Screen
Stock Analysis
Total Stocks Rankings
Archives
July 2008
June 2008
May 2008
April 2008
March 2008
February 2008
January 2008
December 2007